Morten Bagger
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
Journal: Neurology and therapy
Published: October 04, 2022
Response to the letter to the editor regarding our article 'statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study' https://doi.org/10.1002/pst.2233.
Journal: Pharmaceutical statistics
Published: June 27, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 01, 2022
Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys.
Journal: Reproductive toxicology (Elmsford, N.Y.)
Published: October 19, 2021
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 04, 2021
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
Journal: Pharmaceutical statistics
Published: April 16, 2021
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.
Journal: Haematologica
Published: August 06, 2020
Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: November 08, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026